Clinical trial
Study of WVE-003 in Patients With Huntington's Disease
NCT05032196 · Wave Life Sciences Ltd., Industry · Completed
Key facts
| NCT number | NCT05032196 |
|---|---|
| Title | Study of WVE-003 in Patients With Huntington's Disease |
| Official title | A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease (SELECT-HD) |
| Lead sponsor | Wave Life Sciences Ltd., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Huntington Disease |
| Intervention type | Drug |
| Interventions | SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003, SAD: Pooled Placebo, MD: 30mg WVE-003, MD: Placebo |
| Enrollment | 47 |
| Start date | Sep 6, 2021 |
| Primary completion | May 24, 2024 |
| Completion | May 24, 2024 |
| First posted | Sep 2, 2021 |
| Last update posted | Aug 12, 2025 |
| Countries | Australia, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: